Magnetic-Fe/Fe₃O₄-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages

• Hongwang Wang,
• Tej B. Shrestha,
• Matthew T. Basel,
• Raj K. Dani,
• Gwi-Moon Seo,
• Sivasai Balivada,
• Marla M. Pyle,
• Heidy Prock,
• Olga B. Koper,
• Prem S. Thapa,
• David Moore,
• Ping Li,
• Viktor Chikan,
• Deryl L. Troyer and
• Stefan H. Bossmann

Beilstein J. Nanotechnol. 2012, 3, 444–455, doi:10.3762/bjnano.3.51

• to the tumor site is highly desirable in cancer treatment, because it is capable of minimizing collateral damage. Herein, we report the synthesis of a nanoplatform, which is composed of a 15 ± 1 nm diameter core/shell Fe/Fe3O4 magnetic nanoparticles (MNPs) and the topoisomerase I blocker SN38 bound

• the payload of tumor-homing double-stable RAW264.7 cells; (2) Release of chemotherapeutic SN38 at the cancer site by means of the self-containing Tet-On Advanced system; (3) Provide localized magnetic hyperthermia to enhance the cancer treatment, both by killing cancer cells through magnetic heating

• of hyperthermia with radiation therapy and chemotherapy can greatly improve the efficacy of cancer treatment [30][31]. Ultrasmall magnetic nanoparticles generate heat efficiently in an alternating magnetic field (AMF). Due to their superior properties, such as negligible or low toxicity